Objective: Advances in genomewide association studies have made possible the return of genetic risk results for complex diseases. Two concerns about these results are (a) negative psychological consequences and (b) viewing probabilistic results as deterministic, leading to misinterpretation and inappropriate decisions. The present study evaluates these concerns through a meta-analytic review of existing literature. Method: Seventeen genetic testing studies of complex disease, including 1,171 participants and reporting 195 effects, 104 of which were unadjusted for covariates, were meta-analyzed under a random effects model. Diseases included Alzheimer's, cardiovascular and coronary heart disease, lung cancer, melanoma, thrombophilia, and type II diabetes. Six domains of behavioral-psychological reactions were examined. Results: Carriers showed significantly increased self-reported behavior change compared to noncarriers when assessed 6 months or later after results return (Hedges's g ϭ .36, p ϭ .019). Conclusions: Return of genetic testing results for complex disease does not strongly impact self-reported negative behavior or psychological function of at-risk individuals. Return of results does appear to moderately increase self-reported healthy behavior in carriers, although research on objectively observed behavior change is needed. This is a growing area of research, with preliminary results suggesting potential positive implications of genetic testing for complex disease on behavior change.
The return of genetic test results in the population at large is increasingly feasible as the cost of genome sequencing drops and knowledge about genotype-disease relationships increases (Mardis, 2011; Ritchie, Holzinger, Li, Pendergrass, & Kim, 2015) . To date, hundreds of thousands of individual whole genome sequences have been generated, including individual research studies that have sequenced over 10,000 individuals each (Telenti et al., 2016) . An important question is whether and how such data may be returned to the individuals or patients who provided their DNA and, if returned, how those individuals may interpret and be affected by this information. In the traditional clinical genetic test results return model, doctors and genetic counselors act as conduits and gatekeepers. They order, interpret, and return results from genetic tests of targeted genomic loci for specific medical purposes (Yu, Jamal, Tabor, & Bamshad, 2013) . The system is not structured to return results for hundreds of thousands of individuals, each of whom could be tested at hundreds of millions of known varying sites in their genome, where each variant is, in principle, a candidate for disease-related interpretation.
What is more, interpretations of genetic variants will change over time as research results continue to accumulate. For example, between 1995 and 2015 there were on average about 80,000 updates per year to the Online Mendelian Inheritance in Man (McKusick-Nathans Institute of Genetic Medicine, 2016a) database. From 2005 to 2015 there were an average of nearly 4,000 new entries each year in the NHGRI-EBI Catalog of published genomewide association studies, a repository of associations between genetic variants and (usually) complex diseases and traits (Burdett et al., 2016; McKusick-Nathans Institute of Genetic Medicine, 2016b) . On the other hand, the number of genetic counselors and physicians available to interpret and return genetic test results is growing slowly. There are currently somewhere between 2,000 and 3,000 licensed practicing genetic counselors in the United States (Bureau of Labor Statistics, 2015a), a number that is not expected to grow rapidly in the coming years (Accreditation Council for Genetic Counseling, 2016; Sarah Lawrence College, 2016) . The number of practicing physicians is larger, of course (Bureau of Labor Statistics, 2015b), but only a small fraction believe they can capably and correctly interpret genetic test results. In a survey of 10,000 physicians, only 10% indicated comfort with genetic-testing results (Christensen, Vassy, et al., 2016; Patay & Topol, 2012) .
Another challenging and central aspect of returning genetic test results is the potential negative emotional and behavioral reactions when individuals learn about their genetic risk for some disease or trait. Individuals who receive genetic test results may overweight or misunderstand disease risk information. Termed genetic essentialism, this is the idea that laypersons view genetic influences as powerful, deterministic, and immutable (Gould & Heine, 2012) . In the case of disease risk, laypersons may see genetic explanations as the main, or only, factor in disease etiology and may be more likely to feel distress or hopelessness when they are presented with genetic risk information (Dar-Nimrod & Heine, 2011) . Indeed, the notion that individuals may be harmed by receiving too much information, or may misinterpret the results they are given, has influenced regulatory positions by the Food and Drug Administration, which has cited the possibility of misinterpretation as a potential source of harm to consumers who engage in direct-toconsumer testing (Food & Drug Administration, 2013) .
Historically, returning results for highly penetrant (often monogenic) disease-related mutations has been a common focus of genetic testing. Extensive reviews over the last few decades have evaluated results return for Huntington's disease, hereditary breast and ovarian cancer, and Lynch syndrome (Hirschberg, ChanSmutko, & Pirl, 2015; Leblond et al., 2011; Meiser & Dunn, 2001) . These reviews generally contend that receipt of carrier status for highly penetrant mutations is related to a number of negative psychological outcomes, including worry (Vansenne, Bossuyt, & de Borgie, 2009 ), general distress (Vansenne et al., 2009) , depression (Leblond et al., 2011; Meiser & Dunn, 2001) , anxiety (Hirschberg et al., 2015; Leblond et al., 2011) , diseasespecific distress (Hirschberg et al., 2015; Leblond et al., 2011) , risk perception (Leblond et al., 2011; Vansenne et al., 2009) , hopelessness (Meiser & Dunn, 2001 ), poorer general well-being (Meiser & Dunn, 2001) , and decreased quality of life (Leblond et al., 2011) , although carrier status is also associated with increases in report of healthy behavior (Leblond et al., 2011) .
The largest effects on these outcomes are seen shortly after receipt of results (Leblond et al., 2011; Meiser & Dunn, 2001) , with a steady tendency of individuals to return to pretesting levels within 6 months of receipt (Meiser & Dunn, 2001) . One significant limitation in this area of research is the lack of long-term followups years after testing (Leblond et al., 2011; Meiser & Dunn, 2001) , which have suggested incipient negative effects of genetic testing for severe disorders like Huntington's (Timman, Roos, Maat-Kievit, & Tibben, 2004) . One review also noted positive behavioral aspects of genetic testing, including improved health and screening behavior in carriers compared to noncarriers (Leblond et al., 2011) .
In contrast to the extensive literature on diseases with large and clear genetic influences, there is relatively little research on complex diseases that show polygenic inheritance. This is due in part to the fact that the effects of individual genetic variants on complex traits are often small and have only in the past few years begun to be discovered through large population-based genetic association studies. It is currently unclear what psychological harms or benefits, if any, can be expected from the return of genetic test results for complex diseases. This is perhaps especially true because the association between carrier status and disease is probabilistic, with most common mutations affecting complex diseases having odds ratios far less than 2 (Manolio et al., 2009 In recent years, studies have begun to directly examine the psychological and behavioral consequences of returning genetic test results for common, complex diseases. Hollands et al. (2016) recently reviewed and meta-analyzed 18 studies comparing individuals randomly assigned to receive genetic test results for a complex disease (regardless of whether they carried a risk allele) versus individuals randomly assigned to not undergo genetic testing. They found no significant differences between these two conditions for outcomes ranging from depression and anxiety to adaptive behavioral changes such as increased sunscreen use to ward off skin cancer. Hollands et al. also conducted subanalyses comparing outcomes between carriers of a risk allele and noncarriers (k ϭ 10 studies included in the subanalyses) but found no significant differences across outcomes with one exception. APOE-e4 carriers for Alzheimer's disease showed significantly increased positive change in dietary supplements compared to noncarriers. Although the carrier versus noncarrier subgroup analysis in Hollands et al. provides suggestive evidence of behavioral change following genetic testing receipt, conclusions are limited by their study inclusion-exclusion criteria, which required every included study to have a control group that never underwent genetic testing in the first place. Although all studies included in Hollands et al. were randomized control trials (RCTs), it is impossible to randomize carriers and noncarriers of a risk allele. As such, the randomized "intervention" arm in Hollands et al. contained two nonrandomized groups (Hollands et al., 2016) .
The Hollands et al. (2016) meta-analysis provides an important first step to evaluate the overall impact of return of genetic testing results for complex disease. The present article builds on this work by conducting a systematic review and meta-analysis of risk allele carrier versus noncarrier comparisons, analogous to the approach used to study the impact of test results for monogenic disorders. To do this, we compared the behavioral and psychological reactions of those who learned they were at higher genetic risk for common complex disease (i.e., carried a risk genotype) versus those who learned they were genetically protected from disease (i.e., did not carry a risk genotype). In contrast to Hollands et al. (2016) , we included all studies that returned carrier status for common, complex disease, regardless of whether a control group was available, which resulted in a total of 17 relevant studies. This comparison of carriers and noncarriers is a crucial test of the psychological and behavioral effects of receiving positive versus negative test results from genetic testing.
We expected that, consistent with the theory of genetic essentialism, participants would show significant and disproportional behavioral change and psychological distress upon receipt of positive test results compared to negative results, even when those test results were positive for variants with small to moderate effects on disease risk. This document is copyrighted by the American Psychological Association or one of its allied publishers.
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Method

Inclusion and Exclusion Criteria
To ensure that the meta-analysis contained studies of only common variants associated with common, complex diseases, we used the effect size associated with the APOE risk allele epsilon-4 (e4). This risk allele is perhaps the most well-known example of a common variant with a large effect on a common complex disease; thus, we used it a benchmark for inclusion. Therefore, any studies returning information for mutations with effect sizes greater than that of a heterozygous APOE e3/e4 carrier (OR vs. e3/e3 carrier ϭ 3.6, 95% confidence interval [3.4, 3.9]; Genin et al., 2011 ) under an additive model were excluded. Conditions where carriers could be already affected and therefore know their carrier status prior to testing, such as Alpha-1 antitrypsin deficiency (Zorzetto et al., 2008) , were also excluded. In total, inclusion criteria were (a) comparison of genetic mutation carriers and noncarriers, (b) test results for a complex disease affected by a genetic mutation with an effect size lower than 3.6 under an additive model, (c) measure(s) of psychological or behavioral outcomes (self-reports or objective measures) after return of results, (d) quantitative measures of outcomes, (e) asymptomatic or unaffected subjects, (f) clear established link between genetic mutation and disease, (g) human, (h) English language, (i) study subjects were of adult age (18ϩ years), and (j) either published in a peer-reviewed journal or an unpublished study or dissertation. Exclusion criteria were (a) test results for high-effect genetic mutations or monogenic disorders such as Huntington's, BRCA1/2 mutations, or Lynch syndrome; (b) hypothetical or vignette-based studies for measuring psychological or behavioral outcomes; (c) lack of comparison between carriers and noncarriers; (d) lack of specific disease or condition caused by or associated with mutation(s) of interest; (e) studies of participants who were already affected or diagnosed participants; (f) lack of quantitative information; (g) nonhuman; (h) pediatric (under 18 years of age); (i) non-English; or (j) meeting abstract, poster presentation, or conference proceeding.
Literature Search
The literature search was conducted in February 2018 using the Web of Science, PsycINFO, and MEDLINE databases. Keywords used in the database searches were combinations of the terms genetic test ‫ء‬ AND (return of result
The search was limited to human studies published in English. In addition, references from studies read in full (detailed later) were examined for potential inclusion, as well as references from studies citing those read in full. The database and reference searches resulted in 4,336 unique articles. Titles and abstracts for all 4,336 articles were screened for inclusion, and 4,292 articles that did not fit the inclusion criteria were excluded. Forty-four articles were read in full, and 17 of these were included in the meta-analysis (see Figure 1 for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA] flowchart of the literature review). Two coders independently reviewed all 44 full-text articles and fully agreed on the inclusion and exclusion of all articles. No unpublished studies, including dissertations, met the inclusion-exclusion criteria. Therefore, all 17 studies included in the meta-analysis were studies published in peer-reviewed journals.
Study Coding
The 17 studies that met inclusion criteria were coded for the following: (a) sample description, (b) disease(s) and genetic mutation(s) of interest, (c) psychological and/or behavioral outcome(s) measured, (d) outcome measurement tools, (e) time point(s) of outcome measurement, and (f) statistics for the calculation of effect sizes. An overview of all included studies, including gene and disease of interest, outcome(s) measured and measurement tools, and time point(s) can be found in Table 1 (See  Table S2 in online supplementary material for a more detailed description of the outcomes). Two coders independently coded each of the 17 included studies. Interrater reliability coefficients (Cohen's kappas for categorical ratings, intraclass correlation coefficients [ICCs] for continuous ratings) for the independent initial coding (prior to discussion and resolution by both coders, as needed) are noted in the next section. By convention, kappas and ICCs Ն .75 denote excellent agreement beyond chance, and kappas and ICCs between .40 and .74 denote fair-to-good agreement (Fleiss, 1981) . Any coding disagreements were resolved by consensus, and the final consensus ratings were used in analyses.
Study Coding Ratings
Information coded for each study included average age of carriers and noncarriers (ICC ϭ 1.00) and the percentage of female carriers and noncarriers (ICC ϭ 1.00); any sample overlap with another included study was also noted. Information coded for disease and gene included disease name(s) (k ϭ 1.00) and specific gene name(s) and/or mutation(s) of interest ( ϭ 1.00). The diseases included were Alzheimer's disease (k ϭ 4), cardiovascular disease (k ϭ 3), coronary heart disease (k ϭ 1), lung cancer (k ϭ 2), melanoma (k ϭ 5), thrombophilia (k ϭ 2), and type II diabetes (k ϭ 1). One study included results for both Alzheimer's disease and cardiovascular disease. This was the only study that included two disease outcomes, and we treated the Alzheimer's results return separately from the Alzheimer's-cardiovascular combined results return. Note that these two conditions (Alzheimer's only vs. Alzheimer's and cardiovascular disease combined) used nonoverlapping sets of participants, so treating them in the meta-analysis as separate samples is justified. The five melanoma studies were all conducted in two unique samples, and overlapping samples were counted only once for analysis. All study samples were Ͼ75% Caucasian or of European ancestry.
Psychological and Behavioral Outcomes Ratings
Three composite measures were constructed from individual effects and used as outcomes in the final meta-analysis: Behavior Change, Behavioral Attitudes, and Other Psychological Distress. These outcomes were measured through either study-specific selfreport questionnaires or previously validated self-report questionnaires (see Table 1 for specific measures used in each study). Although either self-reported or objective measures of outcomes would have met our inclusion criteria, ultimately, all of the included studies and outcomes relied on self-reports. Effects for each outcome were synthesized across type of measure. The Behavior Change category included self-reported measures of concrete changes in health behaviors, such as increases in exercise, diet This document is copyrighted by the American Psychological Association or one of its allied publishers.
change, and enacting preventative measures such as wearing sunscreen. Behavioral Attitudes comprised measures of motivation, confidence, and intention around changing health behaviors and knowledge about one's ability to prevent or alleviate disease risk. The Other Psychological Distress category included psychological outcomes that were not obviously related to clinical measures of anxiety and depression, such as stress, well-being, and overall emotional changes, both positive and negative. Noncomposite measures were Anxiety, Depression, and Disease-Specific Distress. Information coded for each study included the specific psychological (Anxiety, Depression, Disease-Specific Distress, Other Psychological Distress outcomes) and behavioral (Behavior Change, Behavioral Attitudes) outcomes measured ( ϭ 1.00). Information coded for the questionnaires used to measure these study outcomes included the names of validated measures used to assess psychological and behavioral outcomes (e.g., the Impact of Event Scale; Fleiss & Cohen, 1973 ; used to measure DiseaseSpecific Distress) or specification of study-specific self-report questionnaires ( ϭ 1.00). Information coded for the effect size calculations included sample sizes of carrier (ICC ϭ 1.00) and noncarrier (ICC ϭ 1.00) groups and statistics for comparisons between the two groups (ICC ϭ 1.00).
Potential Risk of Study Bias
To assess bias in the studies included in this meta-analytic review, two independent coders reviewed all included studies for potential sources of bias following Cochrane guidelines for nonrandomized studies (all included studies were nonrandomized case-control studies, given that participants cannot be randomly assigned by a researcher to carrier vs. noncarrier groups; Becker & Oxman, 2011) . All included studies were rated for bias (high, low or no, or unclear) in the following categories: selection bias (comparability of carrier and noncarrier groups at baseline; ICC ϭ 1.00), detection bias (blinding of study-outcome assessment personnel to carrier-noncarrier status; ICC ϭ .85), attrition bias (participant attrition at follow-up assessments; ICC ϭ .82), reporting bias (completeness and appropriateness of statistical outcome reporting; ICC ϭ .53), and potential sources of other bias (ICC ϭ 1.00). Any coding disagreements were resolved by consensus.
Data Analysis
Effect sizes for comparing carriers and noncarriers were calculated from each study for each included outcome at each included time point. A Hedges's g and respective standard error were This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
calculated for every reported result from these studies by calculating either a standardized mean difference or a log odds ratio, which was then converted into Hedges's g (Lipsey & Wilson, 2001 ). When a cell had zero observations (e.g., no controls reported feeling "worried"), .5 was added to the cell to estimate a standard error and allow the cell to contribute to the analysis (Lipsey & Wilson, 2001) . Sample overlap was taken into account such that any sample reported on multiple times was counted only once in analysis. Observations taken after receipt of results clustered into three time points: (a) baseline, before testing results were returned; (b) 6 months or sooner after results; and (c) 6 months or longer after results. These time points are referred to as "baseline," "Յ6 months," and "Ͼ6 months" for analysis. The average time of follow-up in the Յ6 months time point was 1.29 months after results return, and the average time of follow-up in the Ͼ6 months time point was 14.14 months after results return. Not every study had an observation in each of the three time point categories. If a study had two or more assessments after results return but before 6 months had passed, we used the earliest measure. If a study had two or more assessments after results return and after 6 months had elapsed, we took the latest assessment possible. This allowed for examination of the most proximal and distal effects on participants. The earliest time points give insight into the most immediate impact of results. There is a lack of studies in the literature focusing on the longitudinal impacts of returning genetic testing results (Hirschberg et al., 2015; Landsbergen, Prins, Brunner, Kraaimaat, & Hoogerbrugge, 2009 ), making it important to examine the furthest possible outcomes to address this gap. An overall Hedges's g effect size, variance, 95% confidence interval, and a p value were calculated for each result at each time point (Lipsey & Wilson, 2001) . Effects from similar measures within a study (e.g., depression and anxiety) are likely correlated to some degree, but accounting for such dependencies among all This document is copyrighted by the American Psychological Association or one of its allied publishers.
measures, including highly study-specific measures such as diseasespecific distress, is not feasible. Hence, we chose to report all outcomes at all time points to retain analytical and interpretive simplicity and generate a set of conservative results that can be interpreted with greater confidence. The effect sizes from each measure were coded in standard meta-analytic format (Lipsey & Wilson, 2001) , with effect sizes coded as positive or negative depending on the outcome in question. For Depression, Anxiety, Disease-Specific Distress, and Other Psychological Distress, a positive effect size (Ͼ0) indicates that carriers reported greater depression, anxiety, or distress than did noncarriers. For Behavior Change and Behavioral Attitudes, a positive effect size (Ͼ0) indicates that carriers reported greater healthy change or healthier attitudes than did noncarriers. All analyses were conducted in R Version 3.2.2 (R Core Team, 2015) . The R package MAd (Del Re & Hoyt, 2014) was used to compute a Hedges's g and variance for each unique effect. Most studies (k ϭ 13) reported multiple measures of one outcome (e.g., two different anxiety questionnaires assessed at Ͻ6 months). All such measures were expected to be highly correlated and thus were aggregated using MAd as though they were correlated at .50 (the default; Wampold et al., 1997) to create one overall "aggregate" effect per outcome per time point, following standard recommendations (Del Re & Hoyt, 2014) . Study effects were then combined in a random-effects meta-analysis using the R package metafor (Viechtbauer, 2010) . Total study heterogeneity was measured with the standard Q statistic and summarized with I 2 , the percentage of the variability in the effect size due to heterogeneity across studies.
Several studies included in the meta-analysis reported only statistics adjusted for covariates, usually accounting for baseline measures, age, sex, education, or other demographic variables. When both unadjusted and adjusted statistics were reported, we used only the unadjusted statistics. We conducted a primary metaanalysis that included only unadjusted statistics; because the unadjusted results were the most robust, we highlight these in the main text of the article. Because this is a nascent field, with only 17 studies, we chose to conduct a secondary meta-analysis of both unadjusted and, if unadjusted statistics were not available, adjusted statistics, to maximize the number of studies and the total metaanalytic sample size. We consider the combined analysis as exploratory and therefore focus almost all attention here on the primary meta-analysis of only unadjusted statistics. (Full results for the combined meta-analysis are presented in the online supplemental materials; for completeness, we also conducted a metaanalysis of adjusted statistics only, also presented in the online supplemental materials. See Peters & Mengersen, 2008, and Voils, Crandell, Chang, Leeman, & Sandelowski, 2011 , for further discussion of including unadjusted and adjusted statistics in metaanalyses).
Results
In total, 219 unique effects were identified and computed from a total of 17 studies. All 17 studies compared individuals who received a positive genetic test result for increased risk of disease (carriers) with individuals who received a negative result (noncarriers). After we removed all but the most proximal and distal measures from return of results, a total of 195 unique effect sizes from 17 studies remained (number of studies at baseline, k ϭ 11; Յ6 months, k ϭ 12; Ͼ6 months, k ϭ 9). Of these 195 effects, 104 were unadjusted and 91 had been adjusted for covariates (baseline, k ϭ 7; Յ6 months, k ϭ 7; Ͼ6 months, k ϭ 5). No studies reported both adjusted and unadjusted effects on the same samples. All baseline measures were taken before return of results, so the baseline effects represent any systematic carrier and noncarrier differences before the effect of disclosure. An overall meta-analytic effect for each of the six outcomes was computed for each of the three time point clusters, resulting in 16 unadjusted meta-analytic effects (no unadjusted data for baseline Other Psychological Distress or Ͼ6 months Behavioral Attitude). Eleven of the total 17 studies reported unadjusted statistics (see Figure 2 for a forest plot of the unadjusted-only meta-analysis). In the separate combined analysis including adjusted and unadjusted statistics, there were 17 overall meta-analytic effects (see the online supplemental materials for more details on the combined meta-analysis).
The meta-analytic outcomes of the analysis ranged from Ϫ.18 to .78. Of the 16 meta-analytic effects computed from unadjusted statistics, one was significant at p Ͻ .050. Carriers were significantly more likely to self-report positive Behavior Change than were noncarriers at the Ͼ6 months time point (k ϭ 5, g ϭ .36, p ϭ .019). The unadjusted-only Behavior Change effects (k ϭ 5) at the Ͼ6 months time point were not significantly heterogeneous, Q(4) ϭ 2.06, p ϭ .724, I 2 ϭ .00%. There was less evidence for significant positive Behavior Change more proximal to return of results at Յ6 months (k ϭ 6, g ϭ .28, p ϭ .105). This Behavior Change outcome Յ6 months after results also had the smallest nonsignificant p value (.105). Unlike the significant Ͼ6 months Behavior Change finding, the Յ6 months Behavior Change effects (k ϭ 6) were significantly heterogeneous, Q(5) ϭ 13.76, p ϭ .017, I 2 ϭ 61.94%. Although the shorter term Յ6 months Behavior Change was not significant, the effect size (g ϭ .28) was similar to the longer term Ͼ6 months Behavior Change finding (g ϭ .36), suggesting the existence of an effect, albeit nonsignificant at the Ͻ6 months time point in the present sample sizes. Indeed, in the more exploratory combined meta-analysis, described in the online supplemental materials, which had a larger number of available studies, both Behavior Change effects were significant (Յ6 months, k ϭ 9, g ϭ .25, p ϭ .038; Ͼ6 months, k ϭ 9, g ϭ .37, p Ͻ .001). Neither effect was heterogeneous.
No other effect was significant in our meta-analysis of unadjusted effects, at any time point. Effect sizes ranged from Ϫ.18 to .78 in the non-Behavior Change outcomes, with p values ranging from .163 to .936. Nearly all effects were in the expected direction, with carriers reporting greater Disease-Specific Distress-DepressionAnxiety than did noncarriers, as well as greater healthy Behavior Change and Behavioral Attitudes, although all these effects were nonsignificant in the present study. For example, the largest single effect in the analysis was carriers reporting more Anxiety than did noncarriers Ͼ6 months after results, but this outcome was both nonsignificant and based on a single effect from a single study (k ϭ 1, g ϭ .78, p ϭ .163). At the earlier (Յ6 months) time point, carriers also reported more Anxiety but again nonsignificantly (k ϭ 3, g ϭ .20, p ϭ .207). Carriers reported less improvement in Behavioral Attitudes than did noncarriers Ͼ6 months after results, although not significantly (k ϭ 3, g ϭ Ϫ.17, p ϭ .289). There was no strong evidence for any increased Disease-Specific Distress or Other Psychological Distress at any time point. In fact, carriers reported lower increases in these outcomes than did noncarriers. This document is copyrighted by the American Psychological Association or one of its allied publishers.
However, these outcomes were based off from only one study each, respectively. None of the other meta-analytic effects showed heterogeneity. With one exception, all these effects remained nonsignificant in the combined meta-analysis (described in the online supplemental materials), even though in all cases except baseline Depression the sample size and number of studies increased. The one exception was that Disease-Specific Distress became significantly associated in the combined analysis (k ϭ 2, g ϭ .38, p ϭ .036), and the result was not heterogeneous. All included studies were rated for bias (high, low or no, or unclear) in the previously mentioned categories of selection, detection, attrition, reporting, and other bias. Selection bias was high in half of the included articles, meaning there were significant baseline differences between carriers and noncarriers, although no difference was detected for any meta-analysis results at baseline. Detection bias was generally unclear, because only four studies provided information regarding blinding. All four of these studies were not blinded. Half of the included studies also had high attrition bias, losing many participants to follow-up, although six studies had no or very little loss to follow-up. Almost all included studies (k ϭ 14) were coded as high risk of reporting bias. Many studies identified in the literature review did not report necessary statistics for inclusion in meta-analysis, instead reporting means without standard deviations or providing graphs that were poorly labeled and not fully described in the article itself. Several of the included studies also failed to report appropriate information for all their measures, so only some information could be utilized. Fourteen of the 17 included studies were rated as high risk for other sources of bias. Often this high risk referred to reliance upon self-reported measures, which are subject to a number of biases themselves (see Table 2 for the full results of bias coding).
Discussion
We conducted a meta-analysis of self-reported behavioral and psychological reactions to receipt of carrier-noncarrier status for complex diseases. This systematic review of the literature included comprehensive searches of several databases combined with a recursive citation search.
The search of published and unpublished articles identified 17 articles that met inclusion-exclusion criteria, all of which appeared in peer-reviewed publications. All included studies compared carriers who received a positive (i.e., who carried a risk genotype) genetic testing result to noncarriers (i.e., who did not carry a risk genotype) and evaluated self-reported psychological or This document is copyrighted by the American Psychological Association or one of its allied publishers.
behavioral changes that stemmed from receipt of these results. Although either self-reported or objective measures were considered for inclusion in the meta-analysis, all 17 studies relied exclusively on self-report. Ten of the 17 studies included genetic testing for either Alzheimer's or melanoma, and eight came from two research groups, limiting generalizability of our findings. Many studies reported only statistics adjusted for covariates, posing an analytical challenge. We chose to conduct a meta-analysis of unadjusted statistics (11 studies) as our primary analysis, but to maximize sample size, we also reported in the online supplemental materials a meta-analysis of all results, regardless of whether the statistics were adjusted or unadjusted. Sample overlap was taken into account, such that any study sample reported on in multiple studies was counted only once. There was evidence of significant positive health-related behavioral change self-reported more frequently by carriers than noncarriers 6 months or longer after receiving genetic test results. In our primary meta-analysis, which included only unadjusted statistics, there was no strong evidence that receipt of genetic test results affected any of the other 16 outcome categories, including Disease-Specific Distress or short-term Behavior Change. This is perhaps surprising, given the many concerns over how individuals will react to genetic risk information. The theory of genetic essentialism would suggest that individuals who receive genetic test results would treat their risk information as immutable and unchangeable and therefore be more likely to have adverse psychological reactions and/or fail to engage in preventative behaviors when presented with genetic information (Dar-Nimrod & Heine, 2011) . We found no evidence that the individuals in these studies operated under an essentialist perspective. Further longitudinal work is needed to examine whether the changes in behavior that carriers self-reported does last past 2 years after return or whether this effect as well will return to baseline levels.
Given the lack of significant adverse psychological reactions coupled with the significant self-reported Behavior Change in carriers, we wanted to examine the Behavior Change effect more closely using Alzheimer's, a disease that currently cannot be prevented or effectively treated and for which the APOE-e4 allele is a large genetic risk factor. Only one of the five studies with unadjusted effects included in the Behavior Change analysis was an Alzheimer's disease study. Under a genetic essentialism hypothesis, one would expect APOE-e4 carriers to show the same behavior as would noncarriers, because neither group can modify its genetic risk (or genetic protection). We did not observe substantial heterogeneity of the significant result in the analysis of unadjusted statistics, indicating that the Alzheimer's result was not distinguishably larger or smaller compared to the other diseases. That is, individuals who carried APOE-e4 reported more engagement with healthy behaviors than did noncarriers. This result is interesting in part because return of results for APOE-e4 carrier status and Alzheimer's disease is not typically recommended (Burke et al., 2013) , because it is not clinically actionable (Green et al., 2013; Hegde et al., 2015; National Society of Genetic Counselors, 2013) , despite its strong effect (Corder et al., 1993) . If our results hold, the participants in these research studies report engaging in healthy behaviors with respect to Alzheimer's, despite the expected ineffectiveness of those behaviors.
The present results complement and extend a recent metaanalysis by Hollands et al. (2016) , in which the authors compared self-reported health behaviors from individuals randomly assigned to receive genetic test results (grouping together carriers and noncarriers) and those randomly assigned to not receive results. Hollands et al. did not find any significant effect of receiving genetic test results on behavioral change. However, they did find in subgroup analyses directly comparing carriers with noncarriers that receiving positive APOE-e4 results led to self-reported increased use of dietary supplements (Hollands et al., 2016 , did not distinguish between unadjusted and adjusted statistics). The present study comprehensively expands on this preliminary result and expands the finding of significant positive changes in risk carriers The present meta-analysis has several limitations that highlight areas of needed future research. Although we conducted a comprehensive, systematic review of the existing literature, including searching multiple databases, reference sections, and citing articles, only a small number of studies were available for inclusion (k ϭ 17). Because these were not RCTs, many of them did not include a control group that did not receive genetic testing. Control groups allow one to evaluate whether information about risk or protective alleles (or both) results in change and allows evaluation of unmeasured factors and secular trends that may not be apparent in comparisons of carriers and noncarriers. Sample sizes within each study tended to be small, and some of the included studies were different reports based on the same sample. The largest study consisted of 111 carriers and 161 noncarriers, perhaps indicating the difficulty in conducting these sorts of studies. Ultimately, 1,171 unique individuals were represented in the included studies (500 carriers and 671 noncarriers). In our primary analysis of only unadjusted statistics, 719 unique individuals were represented (346 carriers and 373 noncarriers).
Another limitation is the small number of individual effects within a given domain at a given time point. Some outcomes were measured for only one, or just a few, effects. In some cases, the effects were correlated to an unknown degree, making adjustment for correlated statistical significance tests difficult or impossible. As we noted earlier, for almost half of the overall outcomes, we did not have access to unadjusted statistics from each included study. This is important, because many studies reported effects adjusted for demographics or other idiosyncratic confounders. Not all outcomes using unadjusted statistics could be properly evaluated, due to lack of availability of unadjusted statistics. The majority of outcomes included in the unadjusted-only meta-analysis were based on three or fewer unique effects each, and many were based off from only one reported effect. However, results from the combined meta-analysis of adjusted and unadjusted effects mirrored those from the unadjusted-only meta-analysis.
Although either self-reported or objective measures satisfied the inclusion criteria, all included studies ultimately relied on selfreport questionnaires to measure outcomes. Recall can be biased or influenced by demand characteristics (Christensen, Roberts, et al., 2016) . As a result, the effect of genetic information on true behavior changes, as opposed to self-reported changes, may be different from that reported here. The majority of studies included Ͼ75% White individuals, likely of European ancestry, although no study indicated this was due to exclusion of other ancestries. Given the differences in allele frequencies between ethnicities, the results of this meta-analysis may be confounded in unknown ways by ancestry. However, this concern is mitigated by largely ancestrally homogeneous samples, as well as the observation that the driving effect of APOE (the most commonly studied mutation) does not show gross allele frequency differences across major ancestral groups.
The present review highlights the lack of research on the consequences of genetic testing for complex disease. Indeed, the long-term effects, spanning Ͼ1 year, of receiving genetic testing results are essentially unknown. To properly assess the impact of genetic information, future research with larger samples, conducted by independent research groups, that assess both proximal and more distal psychological and behavior outcomes, using both subjective self-reports and more objective methods, is needed. It is also critical that such research studies fully report relevant statistics, including unadjusted statistics. Despite the limitations, the results of this meta-analysis suggest that potential benefits from health behavior change are an important factor to consider in discussions about the return of genetic test results for complex disease. This also matches findings from the more robust literature around returning Mendelian risk information, where carriers indicate improved health behavior after receipt of results (Leblond et al., 2011) .
This conclusion may have implications for the process of returning results from genetic testing. If in fact individuals do not report or experience significant lasting harm from return of results, then strict regulation of the return of results for complex disease may be unwarranted. However, the true potential long-term effects of these returns remain unknown, especially in terms of diseasespecific distress, and some individuals may respond in extreme ways to genetic risk information, which is not captured in tests of mean differences reported herein. On the other hand, the results suggest that individuals may benefit from the return of results, for example through increasing or adopting healthy behaviors, even if they are not mitigating specific genetic risks. If this is the case, then strict regulation of return of results for genetic tests of complex disease may do more harm than good.
